Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Curis, Inc. (NasdaqNM:CRIS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Recent Events
Aug 10Earnings Announcement
Location
61 Moulton Street
Cambridge, MA 02138
Phone: (617) 876-0086
Fax: (617) 876-0866
Email: bboni@curis.com
Employees (last reported count): 40
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 29%
·Institutional: 15% (22% of float)
(56 institutions)
·Net Inst. Buying: 709.0K shares (+12.84%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. Curis' product pipeline will include: a product which is currently under regulatory review in the United States, Europe and Australia; products in late-stage clinical development; numerous early clinical and advanced preclinical products; and a discovery engine that combines functional genomics and developmental biology across multiple medical indications. The Company was formed in August 2000 following the merger between Creative Biomolecules, Inc., Ontogeny, Inc., and Reprogenesis, Inc.
More from Market Guide: Expanded Business Description

Financial Summary
Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. For the three months ended 3/31/01, revenues fell 63% to $249 thousand. Net loss totaled $17.8 million, up from $5.8 million. Revenues reflect the absence of contract revenue from Stryker recognized in 2000. Loss also reflects costs associated with the consolidation of three companies and increased amortization and stock-based compensation costs.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 203; after tax earnings were -19,277. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY1999 Compensation
PayExer

Doros Platika, M.D., 47
Pres, CEO, Director
$634K--  
Andrew Uprichard, M.D.
COO
--  --  
George Eldridge, 37
VP, CFO, Treasurer
135K$27K
Bruce Leicher, 44
VP, Gen. Counsel, Sec.
--  --  
Lynn Baird, Ph.D., 52
VP of Regulatory Affairs, QA/QC and Preclinical Devel.
171K--  
Dollar amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CRISAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$3.00 
Recent Price$6.05 
52-Week High
on 8-Sep-2000
$22.50 
Daily Volume (3-month avg)158.2K
Daily Volume (10-day avg)119.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-70.2%
52-Week Change
relative to S&P500
-60.0%
Share-Related Items
Market Capitalization$189.9M
Shares Outstanding31.4M
Float22.3M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$4.88 
EarningsN/A 
Earnings (mrq)-$0.61 
SalesN/A 
Cash (mrq*)$2.12 
Valuation Ratios
Price/Book (mrq*)1.24 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
SalesN/A 
EBITDAN/A 
Income available to common (ttm)-$19.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on AssetsN/A 
Return on Equity (ttm)-12.57%
Financial Strength
Current Ratio (mrq*)7.99 
Debt/Equity (mrq*)0.04 
Total Cash (mrq)$59.0M
Short Interest
As of 8-Aug-2001
Shares Short442.0K
Percent of Float2.0%
Shares Short
(Prior Month)
497.0K
Short Ratio3.65 
Daily Volume121.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.